163 related articles for article (PubMed ID: 36928875)
1. Hydroxyurea treatment for sickle cell anemia during pregnancy and lactation: Current evidence and knowledge gaps.
Dong M; Ware RE; Dallmann A; Vinks AA
Pharmacotherapy; 2023 May; 43(5):419-429. PubMed ID: 36928875
[TBL] [Abstract][Full Text] [Related]
2. Hydroxyurea (hydroxycarbamide) for sickle cell disease.
Nevitt SJ; Jones AP; Howard J
Cochrane Database Syst Rev; 2017 Apr; 4(4):CD002202. PubMed ID: 28426137
[TBL] [Abstract][Full Text] [Related]
3. Pain and other non-neurological adverse events in children with sickle cell anemia and previous stroke who received hydroxyurea and phlebotomy or chronic transfusions and chelation: results from the SWiTCH clinical trial.
Alvarez O; Yovetich NA; Scott JP; Owen W; Miller ST; Schultz W; Lockhart A; Aygun B; Flanagan J; Bonner M; Mueller BU; Ware RE;
Am J Hematol; 2013 Nov; 88(11):932-8. PubMed ID: 23861242
[TBL] [Abstract][Full Text] [Related]
4. Hydroxyurea therapy for sickle cell anemia.
McGann PT; Ware RE
Expert Opin Drug Saf; 2015; 14(11):1749-58. PubMed ID: 26366626
[TBL] [Abstract][Full Text] [Related]
5. Effectiveness and Safety of Hydroxyurea in the Treatment of Sickle Cell Anaemia Children in Jos, North Central Nigeria.
Ofakunrin AOD; Oguche S; Adekola K; Okpe ES; Afolaranmi TO; Diaku-Akinwumi IN; Zoakah AI; Sagay AS
J Trop Pediatr; 2020 Jun; 66(3):290-298. PubMed ID: 31608959
[TBL] [Abstract][Full Text] [Related]
6. Interventions for preventing silent cerebral infarcts in people with sickle cell disease.
Estcourt LJ; Kimber C; Hopewell S; Trivella M; Doree C; Abboud MR
Cochrane Database Syst Rev; 2020 Apr; 4(4):CD012389. PubMed ID: 32250453
[TBL] [Abstract][Full Text] [Related]
7. Implementation of near-universal hydroxyurea uptake among children with sickle cell anemia: A single-center experience.
Karkoska K; Todd K; Niss O; Clapp K; Fenchel L; Kalfa TA; Malik P; Quinn CT; Ware RE; McGann PT
Pediatr Blood Cancer; 2021 Jun; 68(6):e29008. PubMed ID: 33742510
[TBL] [Abstract][Full Text] [Related]
8. Optimizing hydroxyurea therapy for sickle cell anemia.
Ware RE
Hematology Am Soc Hematol Educ Program; 2015; 2015():436-43. PubMed ID: 26637755
[TBL] [Abstract][Full Text] [Related]
9. Absence of hydroxyurea-induced mutational effects supports higher utilisation for the treatment of sickle cell anaemia.
Ware RE; Dertinger SD
Br J Haematol; 2021 Jul; 194(2):252-266. PubMed ID: 33570176
[TBL] [Abstract][Full Text] [Related]
10. Hydroxyurea Dose Escalation for Sickle Cell Anemia in Sub-Saharan Africa.
John CC; Opoka RO; Latham TS; Hume HA; Nabaggala C; Kasirye P; Ndugwa CM; Lane A; Ware RE
N Engl J Med; 2020 Jun; 382(26):2524-2533. PubMed ID: 32579813
[TBL] [Abstract][Full Text] [Related]
11. Hydroxyurea therapy contributes to infertility in adult men with sickle cell disease: a review.
DeBaun MR
Expert Rev Hematol; 2014 Dec; 7(6):767-73. PubMed ID: 25242414
[TBL] [Abstract][Full Text] [Related]
12. Novel use Of Hydroxyurea in an African Region with Malaria (NOHARM): a trial for children with sickle cell anemia.
Opoka RO; Ndugwa CM; Latham TS; Lane A; Hume HA; Kasirye P; Hodges JS; Ware RE; John CC
Blood; 2017 Dec; 130(24):2585-2593. PubMed ID: 29051184
[TBL] [Abstract][Full Text] [Related]
13. Assessment of genotoxicity associated with hydroxyurea therapy in children with sickle cell anemia.
Flanagan JM; Howard TA; Mortier N; Avlasevich SL; Smeltzer MP; Wu S; Dertinger SD; Ware RE
Mutat Res; 2010 Apr; 698(1-2):38-42. PubMed ID: 20230905
[TBL] [Abstract][Full Text] [Related]
14. Hydroxyurea and sickle cell anemia. Clinical utility of a myelosuppressive "switching" agent. The Multicenter Study of Hydroxyurea in Sickle Cell Anemia.
Charache S; Barton FB; Moore RD; Terrin ML; Steinberg MH; Dover GJ; Ballas SK; McMahon RP; Castro O; Orringer EP
Medicine (Baltimore); 1996 Nov; 75(6):300-26. PubMed ID: 8982148
[TBL] [Abstract][Full Text] [Related]
15. Hydroxyurea Exposure in Lactation: a Pharmacokinetics Study (HELPS).
Ware RE; Marahatta A; Ware JL; McElhinney K; Dong M; Vinks AA
J Pediatr; 2020 Jul; 222():236-239. PubMed ID: 32171562
[TBL] [Abstract][Full Text] [Related]
16. Hydroxyurea for sickle cell anemia: what have we learned and what questions still remain?
McGann PT; Ware RE
Curr Opin Hematol; 2011 May; 18(3):158-65. PubMed ID: 21372708
[TBL] [Abstract][Full Text] [Related]
17. Safety of hydroxyurea in children with sickle cell anemia: results of the HUG-KIDS study, a phase I/II trial. Pediatric Hydroxyurea Group.
Kinney TR; Helms RW; O'Branski EE; Ohene-Frempong K; Wang W; Daeschner C; Vichinsky E; Redding-Lallinger R; Gee B; Platt OS; Ware RE
Blood; 1999 Sep; 94(5):1550-4. PubMed ID: 10477679
[TBL] [Abstract][Full Text] [Related]
18. A two-year pilot trial of hydroxyurea in very young children with sickle-cell anemia.
Wang WC; Wynn LW; Rogers ZR; Scott JP; Lane PA; Ware RE
J Pediatr; 2001 Dec; 139(6):790-6. PubMed ID: 11743503
[TBL] [Abstract][Full Text] [Related]
19. Opportunities for model-based precision dosing in the treatment of sickle cell anemia.
Dong M; Mizuno T; Vinks AA
Blood Cells Mol Dis; 2017 Sep; 67():143-147. PubMed ID: 28807656
[TBL] [Abstract][Full Text] [Related]
20. Effect of hydroxyurea in sickle cell anemia: a clinical trial in children and teenagers with severe sickle cell anemia and sickle cell beta-thalassemia.
Koren A; Segal-Kupershmit D; Zalman L; Levin C; Abu Hana M; Palmor H; Luder A; Attias D
Pediatr Hematol Oncol; 1999; 16(3):221-32. PubMed ID: 10326220
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
